Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Oct 14, 2021 7:00am
146 Views
Post# 34004152

RE:RE:Covid test

RE:RE:Covid testThis is off the Alberta Health Services website and is how they explain the use of serology tests. Immusafe's tests could  increase the use of serology tests ..

Serology (Blood) Testing

Serology testing examines a person’s blood to see if they have generated antibodies in response to being infected by the COVID-19 virus. It takes about one to three weeks following an infection for your body to make antibodies, therefore serology testing is only used to identify past exposure to virus and is not used for diagnosing current COVID-19 infections.

Serology testing is not used for diagnostic purposes but is currently being used for surveillance and research purposes to assess the number of people in Alberta who have been exposed to SARS-CoV-2 and to inform some medical treatment decisions. It is not available to the general public in Alberta, and tests must be ordered by a physician and approved by provincial virology experts.

<< Previous
Bullboard Posts
Next >>